UAE, Sept. 24 -- Novartis today convened leading experts from science, policy, patient advocacy, and clinical care to spotlight elevated lipoprotein(a), or Lp(a) - a little-known but highly prevalent genetic risk factor for cardiovascular disease (CVD) that affect 1 in 5 people worldwide.

The global educational webinar, titled "Introducing the Little (a) with Big Consequences", was attended by journalists from leading media publications across the UAE. Held ahead of World Heart Day (29 September 2025), the session was part of a global awareness campaign by Novartis in collaboration with Global Heart Hub to raise awareness of elevated lipoprotein(a) and advance equitable access to testing and care worldwide.

Despite its prevalence, Lp(a)...